

Professor John Gribben

Barts
Cancer Institute
Queen Mary University of London



Research Interests

My main research areas are in haematologic malignancies, particularly leukaemia, and bone marrow transplantation, cancer immunology and clinical trials.

My research group focuses on:

- Immunological approaches to the treatment of haematological cancers.
- Molecular mechanisms whereby cancer cells induce changes in the host immune system.
- The use of allogeneic stem cell bone marrow transplant to induce a graft versus leukaemia effect.
- Identification of the antigenic targets expressed by cancer cells.
- Use of agents that will make tumour cells more susceptible to immune cell mediated killing, without impacting on the host immune system.
- Genetic manipulation of T cell responses against cancer

Major Funders

- CLL Global Alliance
- Medical Research Council
- US NIH – CLL Research Consortium

Contact Details

Email: s.charleson@qmul.ac.uk



Barts and The London
School of Medicine and Dentistry

www.bci.qmul.ac.uk

Professor John Gribben

Barts
Cancer Institute
Queen Mary University of London



Recent Publications

- Liapis K, Clear A, Owen A, Coutinho R, Greaves P, Lee AM, Montoto S, Calaminici M, **Gribben JG**. The microenvironment of AIDS-related diffuse large-B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. *Blood*. 2013. [Epub ahead of print]
- Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, Shanyinde M, Lister TA, Calaminici M, **Gribben JG**. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. *J Clin Oncol*. 2013;31:256-262
- Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. *Blood*. 2013;121:2704-2714
- Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, **Gribben JG**. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. *Blood*. 2013;121:1612-1621.
- Greaves P, **Gribben JG**. The role of B7 family molecules in hematologic malignancy. *Blood*. 2013;121:734-744.3563361
- Ramsay AG, Clear AJ, Fatah R, **Gribben JG**. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. *Blood*. 2012;120:1412-1421.3423779.